Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation: the NCT Neuro Master Match (N2M2) pilot study

AbstractBackground. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status is a predictive biomarker in glioblastoma patients. Glioblastoma

Bibliographic Details

Main Authors:	Pfaff, Elke (Author) , Keßler, Tobias (Author) , Balasubramanian, Gnana Prakash (Author) , Berberich, Anne (Author) , Schrimpf, Daniel (Author) , Wick, Antje (Author) , Debus, Jürgen (Author) , Unterberg, Andreas (Author) , Bendszus, Martin (Author) , Herold-Mende, Christel (Author) , Eisenmenger, Andreas (Author) , Dettmer, Susan (Author) , Brors, Benedikt (Author) , Platten, Michael (Author) , Pfister, Stefan (Author) , Deimling, Andreas von (Author) , Jones, David T. W. (Author) , Wick, Wolfgang (Author) , Sahm, Felix (Author)
Format:	Article (Journal)
Language:	English
Published:	2018
In:	Neuro-Oncology Year: 2017, Volume: 20, Issue: 6, Pages: 826-837
ISSN:	1523-5866
DOI:	10.1093/neuonc/nox216
Online Access:	Verlag, Volltext: http://dx.doi.org/10.1093/neuonc/nox216 Verlag, Volltext: https://academic.oup.com/neuro-oncology/article/20/6/826/4641653
Author Notes:	Elke Pfaff, Tobias Kessler, Gnana Prakash Balasubramanian, Anne Berberich, Daniel Schrimpf, Antje Wick, Jürgen Debus, Andreas Unterberg, Martin Bendszus, Christel Herold-Mende, David Capper, Irini Schenkel, Andreas Eisenmenger, Susan Dettmer, Benedikt Brors, Michael Platten, Stefan M. Pfister, Andreas von Deimling, David T.W. Jones, Wolfgang Wick, and Felix Sahm